Mereo BioPharma
MREO
61 hedge funds and large institutions have $18M invested in Mereo BioPharma in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 17 closing their positions.
826% more call options, than puts
Call options by funds: $287K | Put options by funds: $31K
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
3% less funds holding
Funds holding: 63 → 61 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
11.9% less ownership
Funds ownership: 47.37% → 35.47% (-12%)
28% less capital invested
Capital invested by funds: $24.9M → $18M (-$6.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$339K |
| 2 |
II
Ishara Investments
Los Angeles,
California
|
+$231K |
| 3 |
Jane Street
New York
|
+$190K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$133K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.71M |
| 2 |
NM
Newtyn Management
New York
|
-$1.22M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$152K |
| 5 |
DMKJ
David M. Knott Jr
|
-$99.1K |
MREO Hedge Fund Activity: Q2 2026 in Review
61 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2026, worth a combined $18M — down 28% from $24.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MREO and 15 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was Two Sigma Investments, adding an estimated $339K. The largest seller was EcoR1 Capital, cutting an estimated $3.71M.
- 61 institutional investors held Mereo BioPharma (MREO) as of Q2 2026, down from 63 in Q1 2026.
- Funds reported $18M of Mereo BioPharma stock for Q2 2026, down 28% quarter-over-quarter.
- 15 funds opened new Mereo BioPharma positions in Q2 2026 and 17 closed out, a net change of -2 holders.
- The largest Mereo BioPharma buyer in Q2 2026 was Two Sigma Investments, an estimated $339K added.
- The largest Mereo BioPharma seller in Q2 2026 was EcoR1 Capital, an estimated $3.71M sold.
Based on aggregated 13F filings for Q2 2026.